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Tumor suppressor genea b s t r a c t
Mouse embryonic stem cells (ESCs) express high levels of cytoplasmic p53. Exposure of mouse ESCs to
DNA damage leads to activation of p53, inducing Nanog suppression. In contrast to earlier studies, we
recently reported that chemical inhibition of p53 suppresses ESC proliferation. Here, we conﬁrm that
p53 signaling is involved in the maintenance of mouse ESC self-renewal. RNA interference-mediated
knockdown of p53 induced downregulation of p21 and defects in ESC proliferation. Furthermore, p53
knockdown resulted in a signiﬁcant downregulation in Nanog expression at 24 and 48 h post-transfec-
tion. p53 knockdown also caused a reduction in Oct4 expression at 48 h post-transfection. Conversely,
exposure of ESCs to DNA damage caused a higher reduction of Nanog expression in control siRNA-treated
cells than in p53 siRNA-treated cells. These data show that in the absence of DNA damage, p53 is required
for the maintenance of mouse ESC self-renewal by regulating Nanog expression.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. 1. Introduction
Embryonic stem cells (ESCs) have unlimited ability for self-
renewal and a great potential to differentiate into all cell types
[1]. A network of transcription factors, such as Oct4, Sox2, and Na-
nog, maintains the self-renewal and pluripotency of ESCs [2,3]. The
ability of ESCs to maintain their pluripotency is associated with
their ability to remain in a highly proliferative state. Therefore,
they are characterized by an abbreviated cell cycle, which induces
rapid cell division [4]. Nanog is an essential transcription factor, re-
quired for maintaining self-renewal and pluripotency of ESCs [2,5].
The importance of the tumor suppressor, p53, in stem cell biol-
ogy has recently received great interest. However, the exact mech-
anism whereby p53 regulates stem cell function remains
controversial. It has been found that mouse ESCs express high lev-
els of p53 protein in the cytoplasm under basal conditions [6,7].
Although an earlier study had shown that the p53-mediated re-
sponse is inactive in mouse ESCs due to the cytoplasmic sequestra-
tion of p53 [6], recent studies showed that DNA damage induces
p53 accumulation in the nucleus, leading to ESC differentiationby directly inhibiting Nanog expression in mouse ESCs [8]. Further-
more, it has been recently found that p53 in mouse ESCs can per-
form an anti-differentiation function by regulating the Wnt
signaling pathway [9]. Interestingly, our recent results obtained
by using a p53 chemical inhibitor, piﬁthrin a, showed that p53
might be involved in maintaining mouse ESC self-renewal [10].
The role of p53 in ESCs under basal culture conditions is still not
completely understood. Since p53 chemical inhibitors, such as
piﬁthrin a, may have an effect on other signaling pathways in ESCs,
we wanted to investigate the role of p53 in mouse ESCs under un-
stressed conditions by speciﬁc knockdown of the p53 gene using a
small interfering RNA (siRNA) technique. Our results conﬁrmed
that under unstressed culture conditions, p53 expression is re-
quired for maintenance of ESC self-renewal by regulating Nanog
expression.2. Material and methods
2.1. Embryonic stem cell culture
Mouse ESCs (E14TG2a) (CRL-1821; American Type Culture
Collection, Manassas, VA) were cultured as we previously
described [11,12]. Brieﬂy, mouse ESCs were maintained in
DMEM/F-12 medium (Sigma), supplemented with 1000 U/mL leu-
kemia inhibitory factor (LIF; Chemicon), 11% fetal bovine serum,
2 mM L-glutamine (Nacalai Tesque, Japan), 1 mM sodium pyruvate
(Sigma), 1% MEM nonessential amino acids (GIBCO), 0.1 mM
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were cultured under feeder-free conditions in the presence of LIF.
Mitomycin C (MMC) was added to the cultured ESCs at a concen-
tration of 5 lg/mL as previously reported [13].2.2. RNA interference
RNA interference in mouse ESCs was carried out according to
the manufacturer’s protocol using Lipofectamine RNAiMAX (Invit-
rogen). Two independent siRNAs (Invitrogen), which target differ-
ent regions of the p53 mRNA (NM_011640) were designed using
the BLOCK-iT RNAi Designer software. p53 siRNA1 gave a higher le-
vel of p53 knockdown and therefore was used for most of the
experiments. The appropriate siRNA negative control Duplex
(Cat. No. 12935-300; Invitrogen) was selected based on the G/C
percentage. The p53 siRNAs and control siRNA were transfected
at a ﬁnal concentration of 40 nM for 24 h in triplicate for each
treatment. The sequences of the p53 siRNAs are given in Supple-
mentary table 1.2.3. Reverse transcription-polymerase chain reaction
Experiments were performed as described [12]. A detailed
description is given in Supplementary information.2.4. Western blotting
Total protein extracts were prepared from mouse ESCs, dis-
solved in SDS–PAGE buffer, and transferred onto polyvinylidene
diﬂuoride membranes. Proteins were detected using antibodies
against Oct4 (1:1000, sc-5279; Santa Cruz Biotechnology), Nanog
(1:8000, A300-397A; Bethyl Laboratories), p53 (1:500; Santa Cruz
Biotechnology) and b-actin (1:8000, sc-47778; Santa Cruz Biotech-
nology). The secondary antibodies were peroxidase-conjugated
anti-rabbit IgG or peroxidase-conjugated anti-mouse IgG (all
1:10000; Jackson ImmunoResearch Lab). The blots were developed
using SuperSignal West Pico Chemiluminescent substrate (Pierce;
Thermo Fisher Scientiﬁc Inc.), and visualized using an LAS-3000
FujiFilm Lumino-Image Analyzer (FujiFilm, Tokyo, Japan).2.5. Immunoﬂuorescence
Immunoﬂuorescence analysis was performed as described
[12,13]. A detailed description is given in Supplementary
information.3. Bromodeoxyuridine (BrdU) incorporation
BrdU incorporation was performed as described [10]. A detailed
description is given in Supplementary information.3.1. Apoptosis assay
Annexin V staining was performed using ﬂow cytometry as pre-
viously described [13].3.2. Self-renewal assay
Two days after siRNA transfection ESCs were seeded at low den-
sity (2000 cells per 35 mm dish) in the presence of LIF for 3 or
6 days to form secondary ESC colonies. The formed ESC colonies
were stained with crystal violet.3.3. Statistical analysis
The results are expressed as mean ± standard deviation, as indi-
cated in the ﬁgure legends. Statistical signiﬁcance was assessed by
two-tailed Student t tests. Values of P < 0.05 were considered
signiﬁcant.4. Results and discussion
4.1. Knockdown of p53 using small interfering RNA
Previous studies reported that under basal conditions (un-
stressed ESCs), undifferentiated mouse ESCs express a high level
of p53, mainly localized to the cytoplasm [6,7]. Furthermore, re-
cent evidence demonstrated that expression of p53 in mouse ESCs
may be functional under basal (unstressed) conditions [9]. There-
fore, in the current study, the role of p53 was examined in undiffer-
entiated mouse ESCs under unstressed conditions by inhibiting
p53 expression using siRNAs. The efﬁciency of p53 knockdown
was examined 48 h after siRNA transfection. RT-PCR and western
blot analyses showed a marked reduction in the level of p53 mRNA
and protein at 48 h post-transfection in ESCs transfected with p53-
targeting siRNA (p53 siRNA1 and p53 siRNA2), compared with
ESCs transfected with a non-targeting siRNA (control siRNA)
(Fig. 1A–C).
As expected, the knockdown of p53 was accompanied by a dra-
matic reduction in the levels of p21 (CDKN1A) mRNA, which is one
of the downstream targets of p53 (Fig. 1D), suggesting that p53 is
transcriptionally active in mouse ESCs.4.2. Effect of p53 knockdown on ESC self-renewal
The effect of p53 knockdown on mouse ESC proliferation was
evaluated. The ability of siRNA-treated ESCs to form secondary col-
onies was examined by replating ESCs at low density in the pres-
ence of LIF 2 days after transfection. After 6 days in culture, the
number of formed colonies of p53 siRNA-treated ESCs was notably
decreased in comparison to those of control siRNA-treated cells
(Fig. 1E). To further conﬁrm this result, DNA synthesis was mea-
sured using ﬂow cytometry. Control siRNA and p53 siRNA-treated
cells were exposed to BrdU, and its incorporation into ESCs was
quantiﬁed by ﬂow cytometry. ESCs were tested 48 h after siRNA
transfection, following pulsed incorporation of BrdU (45 min). Flow
cytometric analysis of BrdU, which was performed concurrently
with the analysis of the cellular DNA content, showed a reduction
in BrdU incorporation in ESCs treated with p53 siRNA in compari-
son to control siRNA-treated cells (Fig. 1F), suggesting an effect of
p53 on the DNA synthesis of ESCs. Although these results disagree
with an earlier report showing that p53/ ESCs proliferate faster
than p53+/ ESCs [14], they agree with the recent observation of
Solozobova et al. [7], who found that mouse ESCs deﬁcient in
p53 grow slower in comparison with their parental counterpart;
this suggests the involvement of p53 in promoting mouse ESC pro-
liferation. Also, this effect is similar to that observed in melanoma
cells, where p53 knockdown reduces proliferation of melanoma
cells [15]. Furthermore, these ﬁndings concur with our recent re-
sults, which showed a reduction in mouse ESC proliferation after
chemical inhibition of p53 under unstressed culture conditions
[10].
To investigate the effects of p53 knockdown on ESC viability,
cell apoptosis was examined in siRNA-treated ESCs using ﬂow
cytometry for annexin V-positive cells. We found that p53 inhibi-
tion had no effect on ESC viability, since there were no signiﬁcant
changes in the percentage of annexin V-positive cells after p53
Fig. 1. Knockdown of p53 using siRNA and its effect on mouse ESC proliferation. (A) RT-PCR analysis of ESCs transfected with control siRNA or p53 siRNAs, showing
knockdown of p53 mRNA 48 h after siRNA transfection. (B) Western blot analysis of ESCs treated as described in panel A, showing reduced levels of p53 protein 48 h after
siRNA transfection. (C) Quantitative analysis of western blots as shown in panel B. (D) RT-PCR analysis for p21 in ESCs 48 h after siRNA transfection. (E) Photographs of the
formed colonies 6 days after siRNA transfection, stained with crystal violet. (F) Flow cytometric analysis of BrdU incorporation in ESCs treated as in panel A. (G) Apoptosis
assay of ESCs treated as in panel A. The number shows the percentage of annexin V-positive cells. Data represent mean ± s.d. (n = 3); ⁄P < 0.05 or ⁄⁄P < 0.01.
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chemical inhibition of p53 [10].
We also evaluated colony morphology of siRNA-treated ESCs
cultured in the presence of LIF. ESCs, reseeded at low density,
showed that the majority of colonies formed by the p53 siRNA-
treated cells appeared differentiated or partially differentiated
compared to those treated with control siRNA (Fig. 2A). These ﬁnd-
ings suggest that loss of p53 may make ESCs more prone to
differentiation.
4.3. p53 knockdown inhibits Nanog expression
To determine the effect of p53 knockdown on ESC pluripotency
markers, Nanog and Oct4 expression were examined. We found
that Nanog mRNA levels were dramatically reduced in ESCs treated
with p53 siRNA compared to control siRNA-treated cells, while
there was no change in the expression level of Oct4 at 24 h after
siRNA transfection (Fig. 2B). A similar result was obtained by
immunoﬂuorescence analysis at 24 h (Fig. 2C). However, at 48 h
post-transfection, immunoﬂuorescence showed that both Nanog
and Oct4 proteins were reduced in p53 siRNA-treated cells, com-
pared to control siRNA-treated cells (Fig. 2D). To conﬁrm these
observations, western blotting was performed at 24 and 48 h
post-transfection. We found that the protein expression of Nanog
was signiﬁcantly downregulated at 24 and 48 h (Fig. 3A and B).
However, Oct4 protein expression was not signiﬁcantly affected
at 24 h, whereas it was downregulated at 48 h (Fig. 3A and C), sug-
gesting that loss of Nanog expression, rather than Oct4, may be the
initial response to p53 knockdown. The transcription factors Nanog
and Oct4 play a crucial role in maintaining ESC pluripotency [2,3].
Furthermore, it has been shown that transient suppression of
Nanog in mouse ESCs makes them prone to differentiation [16].
Taken together with the morphological changes, these ﬁndings
suggest that loss of p53 may partially promote ESC differentiation
through its effect on Nanog expression.
Since p53 is associated with Nanog suppression after exposure
of ESCs to DNA damage [8], it is unexpected to ﬁnd that p53 knock-
down suppresses Nanog expression. These ﬁndings may suggest
that p53 may play different roles in mouse ESCs as previously sug-
gested [9,10]. This ﬁnding agrees with our recent results, showedthat piﬁthrin-a, the p53 inhibitor, leads to repression of Nanog
expression [10]. Also, a recent study has found that p53 in mouse
ESCs can perform an anti-differentiation function by regulating
the Wnt signaling pathway [9]. Furthermore, since under un-
stressed conditions p53 is mainly localized in the cytoplasm, it
suggests that p53 in the cytoplasm may perform different function
from p53 in the nucleus of mouse ESCs.
Overexpression of Nanog in ESCs inhibits their differentiation
induced by different stimuli, such as withdrawal of LIF or treat-
ment with retinoic acid [5]. Furthermore, it has been found that
a 50% reduction in the level of Nanog expression in ESCs results
in spontaneous differentiation [2]. Therefore, the downregulation
of Oct4 after 48 h may be as a result of differentiation, which
was induced by a dramatic loss of Nanog expression.
Furthermore, p53 siRNA-treated cells exhibited a phenotype of
differentiation after replating at low density. However, in our pre-
vious study, chemical inhibition of p53 using piﬁthrin-a showed
no change in the expression level of Oct4 and there were no signs
of ESC differentiation [10]. One possible explanation for these vari-
ations is that Nanog suppression induced by piﬁthrin-amay be not
sufﬁcient to induce Oct4 inhibition and subsequently ESC differen-
tiation was not observed. It has been reported that to induce ESC
differentiation, a greater than 50% reduction in Oct4 expression is
required [17]. Another explanation is that piﬁthrin-a, in addition
to p53, may affect other signaling pathways in a p53-independent
manner as previously reported [18]. Therefore, further studies
using different technical approaches are needed to clarify the spec-
iﬁcity of p53 chemical inhibitors and whether they affect other sig-
naling pathways in ESCs.
4.4. Knockdown of p53 prevents Nanog suppression after exposure to
DNA damage
The exposure of ESCs to DNA-damaging agents leads to activa-
tion and accumulation of p53 in the nucleus and subsequent inhi-
bition of Nanog expression in mouse ESCs [8]. In response to DNA
damage, the nuclear accumulation of p53 is associated with the
induction of p53 post-translational modiﬁcations, required to sup-
press Nanog expression in mouse ESCs [8]. To examine the effect of
p53 knockdown on Nanog expression after exposure of mouse ESCs
Fig. 2. Effects of p53 knockdown on pluripotency of mouse ESCs. (A) Morphology of ESCs treated with control siRNA or p53 siRNA, 3 days after replating at low density. (B)
RT-PCR analysis of Nanog and Oct4 mRNA 24 h after ESC transfection with the control siRNA or p53 siRNA. (C) Immunoﬂuorescence images of ESCs treated as in panel A for
24 h, stained with antibodies against Nanog and Oct-4, and counterstained with Hoechst reagent. (D) Immunoﬂuorescence images of ESCs treated as in panel C for 48 h and
stained as in panel C. Bar = 20 lm.
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DNA damage p53/apoptosis pathway [19]. We found that treat-
ment of undifferentiated mouse ESCs with MMC (5 lg/mL) for
6 h led to a dramatic increase in p53 levels and a signiﬁcant de-
crease in Nanog levels (Fig. 4A). Therefore, 24 h after siRNA trans-
fection, control and p53 siRNA-treated ESCs were further treated
with MMC for 6 h [13], and the expression of p53 and Nanog was
examined using Western blotting. As expected, we found that
MMC treatment induced a dramatic increase in the level of p53
protein in control siRNA-treated cells, whereas the p53 siRNA-
treated cells showed no increase in the level of p53 protein, indi-
cating that MMC could not activate p53 due to its siRNA-mediated
suppression (Fig. 4B). In contrast to the non-MMC-treated (un-
stressed) ESCs (Fig. 4B and C), we found that the level of Nanog
protein was signiﬁcantly higher in p53 siRNA-treated ESCs than
in the control siRNA-treated ESCs after treatment with MMC
(Fig. 4A and D). These ﬁndings suggest that in the absence of
p53, Nanog does not respond to DNA damage, which support the
hypothesis that repression of Nanog is linked to nuclear accumula-
tion of p53 [8]. Furthermore, these data conﬁrm a novel role for
p53 in regulating Nanog expression in mouse ESCs under un-
stressed culture conditions.
Since most of the previous studies focused on the role of p53
during DNA damage in ESCs, it is interesting to report a novel func-
tion of p53 in maintaining ESC self-renewal by regulating Nanog
expression. Although a previous study reported that p53 directly
suppresses Nanog transcription in mouse ESCs in response toDNA damage [8], a recent study revealed that p53 does not bind
to the Nanog gene during DNA damage of mouse ESCs [20], sug-
gesting that p53 may not directly inhibit ESC pluripotency in re-
sponse to DNA damage [21]. However, recent evidence
demonstrates that in mouse ESCs, p53 induces the expression of
Wnt ligand genes in response to DNA damage to delay the differen-
tiation of neighboring cells, indicating that p53 performs an anti-
differentiation role by directly regulating the Wnt signaling path-
way [9]. Wnt signaling is crucial for maintaining ESC pluripotency
[22]. Therefore, it has been suggested that p53 plays dual roles in
mouse ESCs in response to DNA damage. First, p53 suppresses
Nanog expression leading to differentiation of mouse ESCs [8].
Second, p53 activates the Wnt signaling pathway leading to sup-
pression of the differentiation of mouse ESCs [9]. On the other
hand, our current and previous studies [10] suggest an additional
role for p53 in maintaining the self-renewal of mouse ESCs by reg-
ulating Nanog expression in the absence of stress. It is not surpris-
ing for p53 to be involved in opposite functions in the same cell
type since p53 can be present inside the cells in different forms
depending on its cellular localization and post-translational modi-
ﬁcations, which are associated with different signaling pathways.
Similar ﬁndings have been reported in somatic cells, where p53
has been found to be involved in two opposite roles, activating
both prosurvival genes as well as apoptotic genes [23,24].
Previous studies showed that mouse ESCs differ from human
ESCs in numerous aspects [25]. For example, mouse ESCs depend
on LIF for self-renewal [26], while human ESCs depend on basic
Fig. 3. Knockdown of p53 inhibits the expression of Nanog and Oct4 in mouse ESCs. (A) Representative protein blot of Nanog and Oct4 proteins in ESCs treated with control
small siRNA or p53 siRNA for 24 and 48 h. b-actin was used as a loading control. (B) Quantitative analysis of Nanog protein shown in panel A. (C) Quantitative analysis of Oct4
protein shown in panel A. Data represent mean ± s.d. (n = 3); ⁄P < 0.05 or ⁄⁄P < 0.01.
Fig. 4. Knockdown of p53 prevents Nanog suppression after exposure to DNA damage in mouse ESCs. (A) Representative protein blot of p53 and Nanog in ESCs treated with or
without MMC for 6 h. (B) Representative protein blot of p53 and Nanog treated with control siRNA or p53 siRNA in the presence or absence of MMC for 6 h. (C) Quantitative
analysis of Nanog protein in the absence of MMC (-MMC) shown in panel B. (D) Quantitative analysis of Nanog protein in the presence of MMC (+MMC) shown in panel B.
Data represent mean ± s.d. (n = 3); ⁄P < 0.05 or ⁄⁄P < 0.01 (two-tailed t test).
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ulate that the p53-dependent mechanisms in mouse ESCs are dif-
ferent from human ESCs. Certainly, under standard conditions,
p53 is highly expressed in the cytoplasm of mouse ESCs, whereas
it is expressed at low levels in the nucleus of human ESCs similar
to somatic cells [28]. Also, the response to DNA damage is different,
with activation of p53 in mouse ESCs suppressing Nanog expres-
sion, while in human ESCs, both Nanog and Oct4 are suppressed
[29,30]. Moreover, unlike mouse ESCs, in response to DNA damage,
p53 induces cell cycle arrest in human ESCs [31], and plays a role inthe cell cycle G2/M checkpoint [32]. Furthermore, it has been
found that p53 transcriptional activity differs between mouse
and human ESCs. In mouse ESCs, although binding of p53 at Nanog
was not found, the differentiation-associated genes are activated
and ESC-speciﬁc genes are suppressed in response to DNA damage
[20]. In contrast, in human ESCs, p53 targets a different set of genes
during differentiation versus DNA damage [21]. These differences
may be attributed to the distinction in the origin of both cell types:
inner cell mass (mouse ESCs) versus epiblast (human ESCs) [33].
Taken together with our results, these data suggest that p53
E.M. Abdelalim, I. Tooyama / Biochemical and Biophysical Research Communications 443 (2014) 652–657 657performs its function in different ways according to the source and
type of cells, and indicate the species-speciﬁc difference in p53
function in ESCs.
In conclusion, studies of p53 are numerous, but few focus on its
role in ESCs under basal culture conditions. Although p53 inhibits
pluripotency after DNA damage responses in mouse ESCs, our ﬁnd-
ings suggest another role for p53 in maintaining ESC self-renewal
under unstressed conditions. Taken together with previous studies,
p53 appears to be involved in several functions in mouse ESCs
depending on its cellular localization and the state of the culture
conditions. On the one hand, in the presence of DNA damage,
p53 is translocated to the nucleus, where it induces apoptosis
and differentiation of mouse ESCs. On the other hand, under un-
stressed culture conditions, p53 is mainly localized in the cyto-
plasm, where it maintains the self-renewal of mouse ESCs by
regulating Nanog expression. Also, it can be deduced from these
ﬁndings that there is a difference in the p53 pathway between
mouse ESCs and human ESCs. Therefore, further detailed studies
are required to examine the p53 signaling pathway in ESCs.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bbrc.2013.12.030.
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